T
Thierry Bordet
Publications - 42
Citations - 1119
Thierry Bordet is an academic researcher. The author has contributed to research in topics: Olesoxime & Neuroprotection. The author has an hindex of 17, co-authored 41 publications receiving 1038 citations.
Papers
More filters
Journal ArticleDOI
Identification and Characterization of Cholest-4-en-3-one, Oxime (TRO19622), a Novel Drug Candidate for Amyotrophic Lateral Sclerosis
Thierry Bordet,Bruno Buisson,Magali Michaud,Cyrille Drouot,Pascale Galéa,Pierre Delaage,Natalia P. Akentieva,Alex S. Evers,Douglas F. Covey,Mariano A. Ostuni,Jean-Jacques Lacapère,Charbel Massaad,Michael Schumacher,Esther-Marie Steidl,Delphine Maux,Michel Delaage,Christopher E. Henderson,Rebecca M. Pruss +17 more
TL;DR: In vivo and in vitro, TRO19622 rescued motor neurons from axotomy-induced cell death in neonatal rats and promoted nerve regeneration following sciatic nerve crush in mice, suggesting a potential mechanism for its neuroprotective activity.
Journal ArticleDOI
TRO40303, a new cardioprotective compound, inhibits mitochondrial permeability transition.
Sophie Schaller,Stéphanie Paradis,Gladys A. Ngoh,Rana Assaly,Bruno Buisson,Cyrille Drouot,Mariano A. Ostuni,Jean-Jacques Lacapère,Firas Bassissi,Thierry Bordet,Alain Berdeaux,Steven P. Jones,Didier Morin,Rebecca M. Pruss +13 more
TL;DR: Its efficacy in an animal model of myocardial infarctions makes TRO40303 a promising new drug for the reduction of cardiac ischemia-reperfusion injury and a new pharmacological approach to study mPTP regulation.
Journal ArticleDOI
Olesoxime (TRO19622): A Novel Mitochondrial-Targeted Neuroprotective Compound
TL;DR: Olesoxime provided significant protection in experimental animal models of motor neuron disorders and more particularly ALS, and was designated as a promising drug candidate for motor neuron diseases.
Journal ArticleDOI
Olesoxime (cholest-4-en-3-one, oxime): analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel.
TL;DR: Giving olesoxime during the exposure to paclitaxel significantly and permanently reduced the severity of mechano‐allodynia and mechano-hyperalgesia and significantly reduced the amount of sensory terminal arbor degeneration.
Journal ArticleDOI
Neuromuscular defects and breathing disorders in a new mouse model of spinal muscular atrophy.
Magali Michaud,Thomas Arnoux,Serena Bielli,Estelle Durand,Yann Rotrou,Sibylle Jablonka,Fabrice Robert,Marc Giraudon-Paoli,Markus Riessland,Marie-Geneviève Mattei,Emile Andriambeloson,Brunhilde Wirth,Michael Sendtner,Jorge Gallego,Rebecca M. Pruss,Thierry Bordet +15 more
TL;DR: NewSMN2;Smn(-/-) lines carrying one to four copies of the human SMN2 gene, carrying an intermediate phenotype with delayed appearance of motor defects and developmental breathing disorders reminiscent of those found in severe SMA patients are reported.